BACKGROUND & AIMS: Recurrent hepatitis C with ensuing fibrosis is the leading cause of liver allograft loss. We investigated whether histologic features in early posttransplant liver biopsies could predict the rate of fibrosis progression in this population. METHODS: From 1999 to 2007 there were 476 liver transplants performed for hepatitis C at our center. We reviewed all available posttransplant biopsies for these patients; patients were categorized as rapid, intermediate, or slow fibrosers based on their METAVIR fibrosis score at 24 months. Stage F0 biopsies for rapid and slow fibrosers were analyzed histologically and immunohistochemically. RESULTS: We identified 52 rapid fibrosers and 61 slow fibrosers in our cohort. There was a significant increase in the fibrosis progression rate in the group transplanted between 2003 and 2007 compared with between 1999 and 2002. The course of fibrosis progression was determined early in the posttransplant period and the rate was constant. Rapid fibrosers had more hepatocyte apoptosis than slow fibrosers (P = .001), but no difference in hepatitis activity on stage F0 biopsies. Rapid fibrosers also experienced more episodes of acute rejection after transplantation (P < .001). Cytokeratin 19 (CK19) and vimentin expression on F0 stage biopsies could distinguish rapid from slow fibrosers (CK19: area under the curve, 0.71; P = .0034; vimentin: P = .0219). CONCLUSIONS: CK19, vimentin, and hepatocellular apoptosis are promising early markers of rapid fibrosis progression in patients transplanted for hepatitis C. The rate of fibrosis progression is established early in the posttransplant period; this initial rate dictates long-term outcome. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
BACKGROUND & AIMS: Recurrent hepatitis C with ensuing fibrosis is the leading cause of liver allograft loss. We investigated whether histologic features in early posttransplant liver biopsies could predict the rate of fibrosis progression in this population. METHODS: From 1999 to 2007 there were 476 liver transplants performed for hepatitis C at our center. We reviewed all available posttransplant biopsies for these patients; patients were categorized as rapid, intermediate, or slow fibrosers based on their METAVIRfibrosis score at 24 months. Stage F0 biopsies for rapid and slow fibrosers were analyzed histologically and immunohistochemically. RESULTS: We identified 52 rapid fibrosers and 61 slow fibrosers in our cohort. There was a significant increase in the fibrosis progression rate in the group transplanted between 2003 and 2007 compared with between 1999 and 2002. The course of fibrosis progression was determined early in the posttransplant period and the rate was constant. Rapid fibrosers had more hepatocyte apoptosis than slow fibrosers (P = .001), but no difference in hepatitis activity on stage F0 biopsies. Rapid fibrosers also experienced more episodes of acute rejection after transplantation (P < .001). Cytokeratin 19 (CK19) and vimentin expression on F0 stage biopsies could distinguish rapid from slow fibrosers (CK19: area under the curve, 0.71; P = .0034; vimentin: P = .0219). CONCLUSIONS:CK19, vimentin, and hepatocellular apoptosis are promising early markers of rapid fibrosis progression in patients transplanted for hepatitis C. The rate of fibrosis progression is established early in the posttransplant period; this initial rate dictates long-term outcome. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: R Sreekumar; A Gonzalez-Koch; Y Maor-Kendler; K Batts; L Moreno-Luna; J Poterucha; L Burgart; R Wiesner; W Kremers; C Rosen; M R Charlton Journal: Hepatology Date: 2000-11 Impact factor: 17.425
Authors: M Berenguer; L Ferrell; J Watson; M Prieto; M Kim; M Rayón; J Córdoba; A Herola; N Ascher; J Mir; J Berenguer; T L Wright Journal: J Hepatol Date: 2000-04 Impact factor: 25.083
Authors: G Testa; J S Crippin; G J Netto; R M Goldstein; L W Jennings; B S Brkic; B K Brooks; M F Levy; T A Gonwa; G B Klintmalm Journal: Liver Transpl Date: 2000-09 Impact factor: 5.799
Authors: M Berenguer; M Prieto; J M Rayón; J Mora; M Pastor; V Ortiz; D Carrasco; F San Juan; M D Burgueño; J Mir; J Berenguer Journal: Hepatology Date: 2000-10 Impact factor: 17.425
Authors: L Baiocchi; M Angelico; A Petrolati; L Perrone; G Palmieri; S Battista; M Carbone; L Tariciotti; C Longhi; G Orlando; G Tisone Journal: Am J Transplant Date: 2008-03 Impact factor: 8.086
Authors: Rosalyn Díaz; Ji Won Kim; Jia-Ji Hui; Zhaodong Li; Gary P Swain; Keith S K Fong; Katalin Csiszar; Pierre A Russo; Elizabeth B Rand; Emma E Furth; Rebecca G Wells Journal: Hum Pathol Date: 2007-09-27 Impact factor: 3.466
Authors: Nevin Yilmaz; Mitchell L Shiffman; R Todd Stravitz; Richard K Sterling; Velimir A Luketic; Arun J Sanyal; A Scott Mills; Melissa J Contos; Adrian Coterell; Daniel Maluf; Marc P Posner; Robert A Fisher Journal: Liver Transpl Date: 2007-07 Impact factor: 5.799
Authors: Silja H Voutilainen; Silja K Kosola; Jouko Lohi; Aino Mutka; Timo Jahnukainen; Mikko Pakarinen; Hannu Jalanko Journal: Ann Transplant Date: 2020-10-16 Impact factor: 1.530
Authors: Karim Hamesch; Nurdan Guldiken; Mahmoud Aly; Norbert Hüser; Daniel Hartmann; Pierre Rufat; Marianne Ziol; Katharina Remih; Georg Lurje; Bernhard Scheiner; Christian Trautwein; Mattias Mandorfer; Thomas Reiberger; Sebastian Mueller; Tony Bruns; Pierre Nahon; Pavel Strnad Journal: BMC Med Date: 2020-11-12 Impact factor: 8.775